Procalcitonin Market Size and Growth Insights to 2033

The Procalcitonin Market was valued at USD 257.07 million in 2024 and is projected to grow from USD 281.44 million in 2025 to reach USD 955.72 million by 2033, reflecting a strong CAGR of 13.54% during the forecast period. This rapid growth is driven by the increasing prevalence of infectious diseases such as sepsis and respiratory tract infections, along with advancements in diagnostic technologies that make testing faster and more reliable.

📥 Download Sample

Market Overview

Procalcitonin (PCT) has become a vital biomarker for differentiating bacterial infections from viral or inflammatory conditions. Its rapid response within hours of infection and ability to guide antibiotic use have made it indispensable in emergency departments, ICUs, and hospitals. By supporting antibiotic stewardship programs, PCT testing not only improves patient outcomes but also plays a crucial role in combating antibiotic resistance.

Key Market Highlights

Procalcitonin Antibody dominates the type segment
Medical Application leads in applications
North America holds the largest market share

Growth Factors Driving the Market

The rising global burden of sepsis and bacterial infections is a primary driver of market demand. With sepsis responsible for millions of cases and hospital deaths each year, healthcare providers increasingly rely on PCT testing for faster diagnosis and targeted treatment. By reducing unnecessary antibiotic use, PCT testing helps lower resistance risks and improves healthcare efficiency.

Market Restraints

Despite its clinical benefits, cost concerns remain a key restraint. PCT testing is more expensive than conventional markers, which makes adoption challenging in resource-limited regions. Demonstrating cost-effectiveness through long-term outcomes and reduced hospital stays will be crucial for broader acceptance.

Market Opportunities

Growing awareness about PCT testing and antibiotic stewardship is expected to boost adoption. As healthcare systems worldwide focus on combating antibiotic resistance, PCT testing is gaining recognition as a cost-saving and outcome-improving tool. Its ability to cut unnecessary antibiotic use positions it as a strong driver of future growth.

Regional Insights

North America

North America leads the market, with the U.S. reporting 1.71 million sepsis cases annually and sepsis-related costs reaching USD 27 billion. Procalcitonin testing is gaining traction as hospitals seek cost-effective tools to reduce mortality and treatment expenses.

Europe

Europe ranks second, with sepsis being a leading cause of death in countries like the U.K. and Germany. Reports show that reducing sepsis admissions by just 10–30% could save up to 249 million euros annually, highlighting the importance of PCT-guided care.

Product and Technology Insights

Product Type: Procalcitonin Antigen leads due to its direct role in bacterial infection diagnostics.
Technology: Chemiluminescence Immunoassay (CLIA) dominates thanks to its high sensitivity and automation capabilities.
Applications: Medical use cases, especially in sepsis and respiratory infections, drive the majority of demand.
End-Users: Hospitals remain the largest users due to their critical care infrastructure and high patient volumes.

Key Players in the Procalcitonin Market

Thermo Fisher
Roche Diagnostics
bioMérieux
HyTest
BBI Solutions
ProSpec
Wondfo
Ningbo Medicalsystem Biotechnology
Wuhan Easy Diagnosis Biomedicine
Snibe
Vazyme Biotech
Getein Biotech
Hotgen Biotech
Lumigenex
Nanjing Norman Biological Technology
Kitgen
Beijing KeyGen
Beijing Apis

Recent Developments

April 2024 – Bio-Techne Corporation announced a strategic distribution agreement with Thermo Fisher Scientific to expand diagnostic solutions in Europe.

Conclusion

With sepsis cases and antibiotic resistance on the rise, the global procalcitonin market is set for significant growth. Hospitals and diagnostic laboratories are expected to lead adoption, supported by innovations in CLIA technology and rising awareness of PCT’s benefits. As more healthcare systems adopt this biomarker, the procalcitonin market will play a central role in improving patient outcomes and reducing healthcare costs worldwide.

About Us:

Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.